Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745475 | 0.80 | FFAR1 (0.50) | SLC6A4FFAR1KDM5AKDM4CKDM5B | |
| SCHEMBL1746551 | 0.79 | KDM5A (0.41) | SLC6A4FFAR1KDM5AKDM4CKDM5B | |
| SCHEMBL1746743 | 0.77 | KDM5A (0.40) | SLC6A4FFAR1KDM5AKDM4CKDM5B | |
| SCHEMBL1745181 | 0.75 | POLB (0.41) | SLC6A4FFAR1KDM5AKDM4CKDM5B | |
| SCHEMBL1746947 | 0.75 | ACACB (0.45) | GRIN2B | |
| SCHEMBL1744565 | 0.74 | TRPV1 (0.42) | FFAR1KDM5AKDM4CKDM5BKMT2A | |
| SCHEMBL9966871 | 0.73 | KDM5A (0.55) | SLC6A4FFAR1KDM5AKDM4CKDM5B | |
| SCHEMBL1746742 | 0.72 | GFRA3 (0.45) | FFAR1 | |
| SCHEMBL9966872 | 0.72 | KDM5A (0.47) | SLC6A4FFAR1KDM5AKDM4CKDM5B | |
| SCHEMBL9964442 | 0.71 | KDM5A (0.44) | SLC6A4FFAR1LRRK2KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | SLC6A4 847/4885FFAR1 33/4885LRRK2 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.